The Blank Cheque Problem: How Insurers Commit to International Healthcare Spend Before They Know What It Will Cost

There is a moment in almost every international healthcare case when the insurer has to decide with less information than it would ideally like.

A member has been advised to travel abroad. A hospital has reviewed the records. A treatment plan has arrived with an estimated cost. The family is anxious, the case is urgent, and everyone is waiting for approval.

On paper, the insurer appears to know the cost.

In reality, it usually knows the starting number.

That difference is where a large part of the financial risk in international healthcare begins.

I have seen this repeatedly over the years. The initial estimate may look perfectly reasonable, but once the patient arrives, the clinical picture changes. Another investigation is required. The surgeon changes the line of treatment. The hospital stay is extended. An ICU admission becomes necessary. Rehabilitation is added. A drug or implant sits outside the original package.

Sometimes these changes are clinically unavoidable. Sometimes they could have been anticipated. Either way, by the time they happen, the insurer is already financially committed, and the patient is already in another country, and there is no looking back, instead of living with the change of everything.

That is what I mean by the blank cheque problem.

The quotation is only one part of the decision

Insurers are generally very good at looking at limits, exclusions, negotiated tariffs and claims history. But international care creates a different type of exposure because the financial decision is tied so closely to a clinical decision.

Take a fairly common scenario. A member is advised to undergo a complex procedure overseas. The insurer receives an estimate of USD 25,000 from a hospital and has to decide whether to approve it or not.

The obvious question is: Is USD 25,000 within the member's benefit?

The more important questions are often different:

Is this treatment actually necessary? Does it need to happen overseas? Is this the right procedure for this patient? Is this the right hospital? Is there another destination with an equivalent clinical outcome and a lower expected cost? What is included in the estimate, and what is not? What is most likely to push this case beyond USD 25,000?

If those questions are not answered before approval, the insurer is not really approving a budget. It is approving a clinical journey and hoping the financial outcome stays close to the quotation.

That is a risky place to be.

Why international cases become difficult so quickly

The problem is not that hospitals deliberately underestimate every case. Healthcare simply does not behave like a fixed-price commodity.

A quotation is built around assumptions: expected procedure, expected length of stay, expected level of care and an uncomplicated recovery. Real patients do not always follow those assumptions.

International cases make this harder because the payer is often managing the situation from a distance. The hospital may be in India, Turkey, Thailand or the UK. The insurer may be in Kenya, Ghana, Nigeria or the Middle East. Updates are coming through different people. One message is on email, another is on WhatsApp, somebody has called the hospital, and another team member is waiting for an updated estimate.

By the time the insurer understands that the case has materially changed, the additional cost may already have been incurred.

At that point the question is no longer, Should we approve this?

It becomes, The patient is already admitted. What do we do now?

That is why international healthcare cost control cannot begin with the final invoice.

The biggest savings are often made before travel

There is a lot of discussion in insurance about negotiated hospital rates. Rates matter. Package pricing matters. Claims audit matters.

But none of those will correct the wrong treatment decision.

If an unnecessary procedure is approved at a 20% discount, it is still unnecessary expenditure.

If the same clinical outcome could have been achieved at another qualified provider for USD 18,000 instead of USD 30,000, negotiating 5% off the USD 30,000 quotation is not meaningful cost control.

This is why I believe the most important financial work in international healthcare happens before the guarantee of payment is issued.

Before committing funds, the payer should have a much clearer picture of the case: the diagnosis, the proposed treatment, whether the treatment is clinically justified, whether overseas care is necessary, the realistic alternatives, expected length of stay, the likely total cost and the specific events that could cause the budget to move.

This does not remove uncertainty. Nothing in medicine can do that. But it turns unknown risk into visible risk.

And visible risk can be managed.

Approval should not be the point where visibility ends

This is another weakness in the way many international cases are managed today.

A lot of work goes into getting the case approved. Then, once the patient travels, the insurer waits for updates.

That is backwards.

The period after approval is exactly when the original assumptions need to be tested.

If the patient was expected to stay five days and is still admitted on day eight, somebody should know why. If the treatment plan changes, the payer should see that change against the original plan. If a case that was expected to cost USD 20,000 is now tracking toward USD 27,000, the insurer should not discover that when the final invoice arrives.

The case should remain financially and clinically visible throughout the journey.

This is not about interfering with doctors. It is about giving the payer enough information to understand whether the case is progressing broadly as expected and where the financial exposure is moving.

The real gap is not access to hospitals

Most established insurers already have ways to access international hospitals. They may have direct relationships, assistance partners, TPAs, medical travel companies or global networks.

So access itself is rarely the real problem anymore.

The harder problem is what happens around that access.

Who independently validates the treatment before the insurer commits? Who compares the options? Who benchmarks the likely cost? Who identifies the risk of overstay or overbudget? Who monitors whether the treatment pathway changes? Who reconciles the final bill with what was originally approved? Who follows the patient through recovery and records the outcome?

That is where international healthcare still has a significant control gap.

From paying for treatment to controlling the pathway

International healthcare will always involve uncertainty. A patient is not a spreadsheet and a treatment plan cannot be guaranteed to unfold exactly as expected.

But there is a big difference between accepting clinical uncertainty and accepting financial blindness.

An insurer should be able to enter an international case knowing, as far as reasonably possible:

what is being treated, why this treatment is being recommended, why this provider and destination have been selected, what the case should cost, what could change that cost, and how the case will be monitored if the plan changes.

That changes the nature of the approval.

The insurer is no longer saying:

“We have approved overseas treatment.”

It is saying:

“We understand the treatment decision, the expected financial exposure and the conditions under which that exposure may change.”

That is a much healthier position for the payer, and ultimately a better experience for the member as well.

Because the objective should never be simply to spend less on international healthcare.

It should be to make better healthcare decisions before the money is committed - and then stay in control until the patient has recovered.